Shares of Glenmark were among the top losers on the Nifty Midcap 150 index, with the stock declining by 1.81% to Rs 2,094.00. Other top losers on the index included Sundaram Fin, Ola Electric, Aurobindo Pharm, and J. K. Cement.
Glenmark Financial Overview
The following tables summarize the consolidated financial performance of Glenmark.
Quarterly Results:
| Heading | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
| Revenue | Rs 3,244.19 Crore | Rs 3,433.80 Crore | Rs 3,387.55 Crore | Rs 3,256.21 Crore | Rs 3,264.44 Crore |
| Net Profit | Rs 340.24 Crore | Rs 354.49 Crore | Rs 348.03 Crore | Rs 4.38 Crore | Rs 46.97 Crore |
| EPS | 12.06 | 12.55 | 12.33 | 0.16 | 1.66 |
Annual Results:
| Heading | 2021 | 2022 | 2023 | 2024 | 2025 |
| Revenue | Rs 10,943.93 Crore | Rs 12,304.90 Crore | Rs 12,990.11 Crore | Rs 11,813.10 Crore | Rs 13,321.74 Crore |
| Net Profit | Rs 970.09 Crore | Rs 993.65 Crore | Rs 377.40 Crore | Rs -1,830.85 Crore | Rs 1,047.14 Crore |
| EPS | 34.38 | 33.37 | 10.53 | -53.22 | 37.11 |
| BVPS | 250.36 | 334.48 | 348.70 | 278.09 | 313.60 |
| ROE | 13.73 | 10.36 | 3.13 | -19.13 | 11.83 |
| Debt to Equity | 0.66 | 0.40 | 0.46 | 0.13 | 0.25 |
Annual Income Statement:
| Header | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
| Sales | 13,321 | 11,813 | 12,990 | 12,304 | 10,943 |
| Other Income | 113 | 839 | 316 | 166 | 50 |
| Total Income | 13,435 | 12,653 | 13,306 | 12,471 | 10,994 |
| Total Expenditure | 11,829 | 12,100 | 12,088 | 10,732 | 9,258 |
| EBIT | 1,606 | 552 | 1,218 | 1,739 | 1,735 |
| Interest | 207 | 515 | 349 | 298 | 353 |
| Tax | 352 | 1,867 | 491 | 447 | 412 |
| Net Profit | 1,047 | -1,830 | 377 | 993 | 970 |
Quarterly Income Statement:
| Header | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
| Sales | 3,264 | 3,256 | 3,387 | 3,433 | 3,244 |
| Other Income | 26 | 11 | 31 | 39 | 31 |
| Total Income | 3,290 | 3,267 | 3,418 | 3,473 | 3,275 |
| Total Expenditure | 3,137 | 3,193 | 2,910 | 2,952 | 2,773 |
| EBIT | 153 | 74 | 508 | 521 | 501 |
| Interest | 58 | 66 | 52 | 48 | 39 |
| Tax | 48 | 3 | 108 | 118 | 122 |
| Net Profit | 46 | 4 | 348 | 354 | 340 |
| Header | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
| Operating Activities | -827 | -265 | 625 | 1,108 | 1,131 |
| Investing Activities | 2 | 4,560 | -528 | -333 | -675 |
| Financing Activities | 787 | -3,906 | -77 | -520 | -441 |
| Others | 55 | -174 | 13 | 17 | 13 |
| Net Cash Flow | 17 | 215 | 32 | 272 | 27 |
| Header | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
| Share Capital | 28 | 28 | 28 | 28 | 28 |
| Reserves & Surplus | 8,821 | 7,801 | 9,445 | 9,058 | 7,036 |
| Current Liabilities | 5,967 | 5,818 | 5,045 | 4,689 | 4,201 |
| Other Liabilities | 1,233 | 710 | 4,852 | 3,307 | 4,337 |
| Total Liabilities | 16,049 | 14,358 | 19,371 | 17,083 | 15,603 |
| Fixed Assets | 5,251 | 4,804 | 7,380 | 6,837 | 6,452 |
| Current Assets | 9,295 | 7,428 | 9,873 | 8,282 | 7,359 |
| Other Assets | 1,502 | 2,125 | 2,117 | 1,963 | 1,791 |
| Total Assets | 16,049 | 14,358 | 19,371 | 17,083 | 15,603 |
| Contingent Liabilities | 0 | 1,193 | 477 | 559 | 544 |
| Ratio | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
| Basic EPS (Rs.) | 37.11 | -53.22 | 10.53 | 33.37 | 34.38 |
| Diluted EPS (Rs.) | 37.11 | -53.22 | 10.53 | 33.37 | 34.38 |
| Book Value /Share (Rs.) | 313.60 | 278.09 | 348.70 | 334.48 | 250.36 |
| Dividend/Share (Rs.) | 2.50 | 2.50 | 2.50 | 2.50 | 2.50 |
| Face Value | 1 | 1 | 1 | 1 | 1 |
| Gross Profit Margin (%) | 18.50 | 17.22 | 19.97 | 20.21 | 19.50 |
| Operating Margin (%) | 14.85 | 12.30 | 15.27 | 16.25 | 15.45 |
| Net Profit Margin (%) | 7.86 | -12.13 | 2.90 | 8.07 | 8.86 |
| Return on Networth / Equity (%) | 11.83 | -19.13 | 3.13 | 10.36 | 13.73 |
| ROCE (%) | 19.62 | 17.01 | 13.84 | 16.13 | 14.83 |
| Return On Assets (%) | 6.52 | -10.45 | 1.53 | 5.51 | 6.21 |
| Current Ratio (X) | 1.56 | 1.28 | 1.96 | 1.77 | 1.75 |
| Quick Ratio (X) | 1.05 | 0.84 | 1.37 | 1.23 | 1.21 |
| Debt to Equity (x) | 0.25 | 0.13 | 0.46 | 0.40 | 0.66 |
| Interest Coverage Ratios (X) | 11.90 | 3.94 | 7.42 | 8.34 | 6.05 |
| Asset Turnover Ratio (%) | 0.88 | 0.70 | 0.71 | 0.42 | 0.43 |
| Inventory Turnover Ratio (X) | 1.08 | 1.15 | 1.31 | 1.85 | 1.85 |
| 3 Yr CAGR Sales (%) | 4.05 | 3.90 | 10.49 | 11.68 | 9.82 |
| 3 Yr CAGR Net Profit (%) | 2.66 | 37.38 | -30.26 | 3.64 | 9.85 |
| P/E (x) | 41.53 | -18.01 | 44.13 | 13.25 | 13.52 |
| P/B (x) | 4.91 | 3.44 | 1.38 | 1.37 | 1.86 |
| EV/EBITDA (x) | 17.83 | 12.95 | 6.31 | 6.07 | 7.80 |
| P/S (x) | 3.26 | 2.29 | 1.01 | 1.01 | 1.20 |
Glenmark Pharmaceuticals Limited announced a final dividend of Rs 2.50 per share (250%) on May 23, 2025, with the ex-date as September 15, 2025.
Other corporate actions include:
The stock also had a bonus issue with existing ratio of 1 and offered ratio of 1 with ex-bonus date on March 4, 2005.
With the stock's last traded price at Rs 2,094.00, Glenmark was among the top losers on Nifty Midcap 150 at 10:00 am on Monday, 15 Sept 2025.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.
